Ishita Drugs & Industries Board of Directors
Get the latest insights into the leadership at Ishita Drugs & Industries. Learn about the experienced professionals guiding the company's strategy and governance.
| Name | Position |
|---|---|
| Mr. Jagdish Agrawal | Managing Director |
| Mr. Govind Gupta | Director |
| Mrs. Abha Agrawal | Director |
| Mr. Arvind Sapkal | Director |
| Ms. Dhwani Solanki | Additional Director |
Ishita Drugs & Industries Share price
ISHITADR
73
0.14 (-0.19%)Last updated on 4 Sep, 2025 | 15:40 IST
BUYSELL
Today's High
73.00
Today's Low
71.80
52 Week Low
62.35
52 Week High
99.64
The current prices are delayed, login to your account for live prices
LoginIshita Drugs & Industries FAQs
The board at Ishita Drugs & Industries consists of experienced professionals, including Mr. Jagdish Agrawal , Mr. Govind Gupta , and others, overseeing the company’s strategic and corporate governance.
Directors at Ishita Drugs & Industries are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.
As of the latest update, Mr. Jagdish Agrawal is the current chairman at Ishita Drugs & Industries.
Executive directors at Ishita Drugs & Industries are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.
Yes, Ishita Drugs & Industries adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.
At Ishita Drugs & Industries, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.